Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fipamezole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.56 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.56 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.56 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.56 |
| ▸ | HTR1D | P28221 | 1/20 | 0.31 |
| ▸ | HTR1B | P28222 | 1/20 | 0.31 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fipamezole SCHEMBL935549 | 0.99 | ADRA2A (0.57) | ADRA2AADRA2BADRA2CADRA1BHTR1D | |
| Fipamezole SCHEMBL1271449 | 0.99 | ADRA2A (0.57) | ADRA2AADRA2BADRA2CADRA1BHTR1D | |
| Fipamezole SCHEMBL9354688 | 0.90 | ADRA2A (0.52) | ADRA2AADRA2BADRA2CADRA1B | |
| SCHEMBL4626063 | 0.85 | ADRA2A (0.40) | ADRA2AADRA2BADRA2CADRA1B | |
| Atipamezole SCHEMBL3526769 | 0.83 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CADRA1B | |
| Atipamezole SCHEMBL31147780 | 0.83 | ADRA2A (0.50) | ADRA2AADRA2BADRA2CADRA1B | |
| SCHEMBL7642900 | 0.83 | ADRA2A (0.40) | ADRA2AADRA2BADRA2CADRA1B | |
| SCHEMBL8610304 | 0.83 | ADRA2A (0.40) | ADRA2AADRA2BADRA2CADRA1B | |
| SCHEMBL8612885 | 0.83 | ADRA2A (0.40) | ADRA2AADRA2BADRA2CADRA1BHTR1D | |
| Atipamezole SCHEMBL881064 | 0.82 | ADRA2A (0.51) | ADRA2AADRA2BADRA2CADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2502917-A1 | Solid state crystalline forms of 4-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-1H-imidazole | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2012-09-26 | — | — | EP | claimed |
| WO-2012123129-A1 | SOLID STATE CRYSTALLINE FORMS OF 4-(2-ETHYL-5-FLUORO-2,3-DIHYDRO-1H-INDEN-2-YL)-1H-IMIDAZOLE | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2012-09-20 | — | — | WO | claimed |
| EP-1560581-B1 | OROMUCOSAL FORMULATION AND PROCESS FOR PREPARING THE SAME | JUVANTIA PHARMA LTD OY (FI) | 2007-01-10 | — | — | EP | claimed |
| US-20060052429-A1 | Oromucosal formulation and process for preparing the same | SANTHERA PHARMACEUTICALS (SWITZERLAND) LTD. (CH) | 2006-03-09 | — | — | US | claimed |
| EP-1560581-A1 | OROMUCOSAL FORMULATION AND PROCESS FOR PREPARING THE SAME | Oy Juvantia Pharma Ltd (FI) | 2005-08-10 | — | — | EP | claimed |
| WO-2004041271-A1 | OROMUCOSAL FORMULATION AND PROCESS FOR PREPARING THE SAME | OY JUVANTIA PHARMA LTD (FI) | 2004-05-21 | — | — | WO | claimed |
| US-8653122-B2 | Oromucosal formulation and process for preparing the same | SANTHERA PHARMACEUTICALS (SWITZERLAND) LTD. (CH) | 2014-02-18 | — | — | US | disclosed |
| EP-2502917-A1 | Solid state crystalline forms of 4-(2-ethyl-5-fluoro-2,3-dihydro-1H-inden-2-yl)-1H-imidazole | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2012-09-26 | — | — | EP | disclosed |
| EP-1581504-B1 | PROCESS FOR PREPARING SUBSTITUTED IMIDAZOLE DERIVATIVES AND INTERMEDIATES USED IN THE PROCESS | JUVANTIA PHARMA LTD OY (FI) | 2009-03-18 | — | — | EP | disclosed |
| CN-100339368-C | Process for the preparation of substituted imidazole derivatives and intermediates used in the process | JUVANTIA PHARMA LTD OY (FI) | 2007-09-26 | — | — | CN | disclosed |
| US-7223871-B2 | Process for preparing substituted imidazole derivatives and intermediates used in the process | OY JUVANTIA PHARMA LTD. (FI) | 2007-05-29 | — | — | US | disclosed |
| EP-1560581-B1 | OROMUCOSAL FORMULATION AND PROCESS FOR PREPARING THE SAME | JUVANTIA PHARMA LTD OY (FI) | 2007-01-10 | — | — | EP | disclosed |
| US-20060052429-A1 | Oromucosal formulation and process for preparing the same | SANTHERA PHARMACEUTICALS (SWITZERLAND) LTD. (CH) | 2006-03-09 | — | — | US | disclosed |
| US-20060025465-A1 | Process for preparing substituted imidazole derivates and intermediates used in the process | OY JUVANTIA PHARMA LTD (FI) | 2006-02-02 | — | — | US | disclosed |
| CN-1723202-A | Process for preparing substituted imidazole derivates and intermediates used in the process | JUVANTIA PHARMA LTD OY (FI) | 2006-01-18 | — | — | CN | disclosed |
| EP-1581504-A1 | PROCESS FOR PREPARING SUBSTITUTED IMIDAZOLE DERIVATIVES AND INTERMEDIATES USED IN THE PROCESS | Oy Juvantia Pharma Ltd (FI) | 2005-10-05 | — | — | EP | disclosed |
| EP-1560581-A1 | OROMUCOSAL FORMULATION AND PROCESS FOR PREPARING THE SAME | Oy Juvantia Pharma Ltd (FI) | 2005-08-10 | — | — | EP | disclosed |
| WO-2004063168-A1 | PROCESS FOR PREPARING SUBSTITUTED IMIDAZOLE DERIVATIVES AND INTERMEDIATES USED IN THE PROCESS | OY JUVANTIA PHARMA LTD (FI) | 2004-07-29 | — | — | WO | disclosed |
| WO-2004041271-A1 | OROMUCOSAL FORMULATION AND PROCESS FOR PREPARING THE SAME | OY JUVANTIA PHARMA LTD (FI) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025465-A1 | Process for preparing substituted imidazole derivates and intermediates used in the process | HRH2, HRH4, HRH3 | ADRA2A 688/4885ADRA2B 782/4885ADRA2C 1118/4885 |
| US-20060052429-A1 | Oromucosal formulation and process for preparing the same | HRH2, HRH1, CYP8B1 | ADRA2A 1645/4885ADRA2B 1249/4885ADRA2C 1187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.